Hepion Pharmaceuticals, Inc. (HEPA) is a biotechnology company focused on the research and development of therapies for liver diseases and metabolic disorders. Headquartered in the United States, the company aims to utilize its drug candidates to treat diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepion Pharmaceuticals seeks to develop innovative pharmaceutical solutions for patients with these serious health conditions. Shares of Hepion Pharmaceuticals, Inc. (HEPA), listed on the NASDAQ, can be an appealing choice for investors seeking investment opportunities in the biotechnology and liver disease treatment sector.
Feed
There are no posts to show right now.
We use cookies to improve your experience on our site.